The Most Common Inherited Juvenile Macular Degeneration
Think of the macula as a night market that must be swept clean before the next morning's business can begin. The ABCA4 gene is the sweeper assigned to that job, carting away a fatty leftover called lipofuscin before it can pile up between stalls. When ABCA4 fails to do its job properly, nothing clears the debris, and over months and years it buries the very stalls — the photoreceptor cells — that give central vision its sharpness. Stargardt disease is, worldwide, the single most common inherited reason a child or young adult begins losing that sharp central sight, which is exactly why the name comes up so often once a Somali eye doctor starts digging into a young patient's unexplained trouble reading.
No two cases move at the same pace. One child may find schoolwork genuinely difficult by age eight or nine; another carrying a gentler version of the same fault may not notice much until well into their twenties. Because of that spread, the very first task in any evaluation is pinpointing exactly where a given patient sits along that timeline, since every recommendation that follows depends on that one answer.
The earliest sign families usually notice is a child holding books unusually close or squinting hard at a whiteboard from a normal seating distance, long before anyone has thought to suspect the eyes as the cause. Glare from strong daylight or oncoming headlights becomes genuinely uncomfortable rather than merely bright, and colours can start to look a little washed out as the condition progresses. Stepping from bright sunlight into a shaded room often takes noticeably longer to adjust to than it used to. What tends to puzzle families most is how well the child still moves around a room or a compound — walking and running stay essentially unaffected for years, since it is close, detailed vision that takes the hit, not the wider field of view.
More than 800 individual mutations have been mapped across the ABCA4 gene, and the disease only appears when a child receives one faulty copy from each parent, making it a recessive condition. Two parents can each carry a single faulty copy their entire lives without ever showing a symptom, and still have a child affected by the disease — which is why families with no known history of eye trouble are sometimes caught completely off guard. Where parents share close blood ties, the chance that both happen to carry the same fault rises further, and it's one of the first things we ask about at a first visit.
Fundus autofluorescence imaging usually gives the clearest early view, lighting up scattered flecks of lipofuscin around the macula well before anything shows up on an ordinary eye exam. OCT scanning measures how much of the photoreceptor layer is still intact, and electroretinography checks whether the disease has stayed confined to the macula or has started to touch the wider retina. Confirming the ABCA4 mutation through genetic testing gives Somali families a solid, factual basis for deciding how — and when — to have siblings screened, rather than leaving it to guesswork.
Where the evaluation supports it, regenerative stem cell therapy becomes part of a broader plan aimed at protecting whatever central vision remains rather than trying to reverse what has already gone. Because so many patients here are still at school, the plan is deliberately practical — low-vision aids suited to daily classwork, clear advice for teachers on seating and lighting, and a review schedule timed to fit around the academic calendar rather than disrupting it.
It's very unlikely to be the same condition. What your father most likely experienced is age-related macular degeneration, which develops later in life from ageing changes rather than a gene passed through the family. Stargardt disease begins in childhood, follows its own genetic pattern, and is managed quite differently, even though the two touch the same part of the eye.
Treatment is aimed at protecting the vision your child still has and slowing any further loss, rather than reversing what has already gone. That's exactly why a thorough first assessment matters so much — it tells us precisely where things stand and what a realistic outcome looks like from there.
That's genuinely common with a recessive condition like this one. Both parents can carry a single faulty copy of the ABCA4 gene for a whole lifetime without ever having any symptoms, and a child is only affected when they inherit a faulty copy from each parent — so a family with no known history isn't ruled out at all.
It's worth doing. Once one child in a family has a confirmed ABCA4 diagnosis, a baseline eye check for siblings — even those with no complaints — gives a useful starting point and can catch a slower, milder version of the same disease early, while there's the most room to plan ahead.